anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Deep brain stimulation (DBS) is a common procedure in neurosurgery used for the treatment of Parkinson's disease (PD) and essential tremor (ET) among other disorders. Lower urinary tract dysfunction is a common complication in PD, and this study aimed to evaluate the risk factors of postoperative urinary retention (POUR) after DBS surgery in patients with PD compared with patients with ET. Understanding the risk factors associated with this complication may help in the development of strategies to minimize its occurrence and improve patient outcomes.
METHODS: The study was a retrospective analysis of patients who underwent DBS surgery for PD and ET at the University of Florida between 2010 and 2021. The surgical technique used has been described in previous articles and included a two-stage procedure, with stage 1 involving burr hole placement, microelectrode recording, and electrode implantation and stage 2 involving the placement of an implantable pulse generator (IPG). Data were collected on patient characteristics and surgical details and analyzed using univariate and mixed-linear models. Post hoc propensity score matching was used to confirm the association between subthalamic nucleus (STN)-DBS and POUR.
RESULTS: The study included 350 patients (153 with PD and 197 with ET) who underwent 1086 DBS surgeries (lead implantations, IPG placement, and IPG replacements). The POUR rates were 16.6% (79/477), 5.2% (19/363), and 0.4% (1/246) for stage 1, stage 2, and IPG replacement procedures, respectively. Optimal mixed-effects logistic modeling revealed history of urinary retention (OR 9.3, p = 0.004), male sex (OR 2.7, p = 0.011), having an electrode placed or connected for the first time (OR 2.2, p = 0.014), anesthesia time (OR 1.5 for each 30-minute increase, p < 0.0001), preoperative opioid use (OR 1.4 for each additional 10 morphine milligram equivalents, p = 0.032), and Charlson Comorbidity Index (OR 1.4 per comorbidity, p = 0.017) to be significant risk factors for POUR. Having an electrode in the STN was found to be protective of POUR (propensity score-matched analysis: OR 0.2, p = 0.010).
CONCLUSIONS: Most risk factors found to increase the risk of POUR in DBS are not modifiable but are still important to consider in preoperative planning. Opioid use reduction and shorter anesthesia time may be modifiable risk factors to weigh against their alternative. Targeting the STN during DBS may result in decreased rates of POUR. This highlights the potential for STN-targeted DBS in reducing POUR risk in PD and ET patients.
The present invention relates to a process for preparing a mixture of cetylated fatty acids and a system for carrying out said process. Furthermore, the present invention relates to a composition comprising, or alternatively, consisting of said mixture of cetylated fatty acids. Finally, the present invention relates to said composition for use in the treatment and/or prevention of: (i) rheumatoid arthritis of inflammatory and non-inflammatory origin, in particular osteoarthritis; (ii) other inflammatory joint conditions; (iii) psoriasis, lupus, periodontal diseases or cardiovascular or heart diseases; (iv) all post-traumatic osteoarticular pathologies including sports injuries; (v) all degenerative joint pathologies (arthrosis, gonarthrosis, coxarthrosis, etc.), and (vi) inflammatory-traumatic tendon and muscular conditions. Furthermore, it is envisaged that the composition of the present invention be used in the treatment and/or prevention of the above-mentioned pathologies and disorders (i)-(vi) in association with a rehabilitative therapy. The composition comprising said mixture is formulated in a pharmaceutical form for oral use (novel food, supplement or medical device), i.e. in the form of a pill, pastille, capsule, tablet, granules, dispersible powder, syrup, solution or sprayable solution; for topical use, i.e. in the form of a cream, unguent, ointment, gel or spray to be used as such for application on the skin, or else for trans dermal use in the form of a patch.
The present invention is a compound and method for treating and preventing periodontal disease. The compound contains a gum tissue regeneration agent, such as coenzyme Q 10 , and a antimicrobial agent, such as melaleuca alternifolia extract oil, mixed into a solution medium. The compound is applied to the bristles of a brush. The brush then is used to introduce the compound into any pockets that may exist between and around the teeth and gums because of periodontal disease. Once introduced into pockets between the teeth and gums, the compound has a dual effect. First, the antimicrobial agent kills any bacteria in the pockets and prevents the growth of new bacteria in the pockets. Second, the gum tissue regeneration agent promotes growth of the gums against the teeth. As a result, the size of the pockets is reduced over time until the pockets are no longer abnormal and the damage from past periodontal disease is at least partially repaired.
Hyaluronic acid injection is commonly used clinically to slow down the development of osteoarthritis (OA). A newly developed therapeutic method is to implant chondrocytes/stem cells to regenerate cartilage in the body. The curative effect of stem cell therapy has been proven to come from the paracrine of stem cells. In this study, exosomes secreted by stem cells from human exfoliated deciduous teeth (SHED) and hyaluronic acid were used individually to evaluate the therapeutic effect in slowing down OA. SHED was cultured in a serum-free medium for three days, and the supernatant was collected and then centrifuged with a speed difference to obtain exosomes containing CD9 and CD63 markers, with an average particle size of 154.1 nm. SW1353 cells were stimulated with IL-1β to produce the inflammatory characteristics of OA and then treated with 40 μg/mL exosomes and hyaluronic acid individually. The results showed that the exosomes successfully inhibited the pro-inflammatory factors, including TNF-α, IL-6, iNOS, NO, COX-2 and PGE2, induced by IL-1β and the degrading enzyme of the extrachondral matrix (MMP-13). Collagen II and ACAN, the main components of the extrachondral matrix, were also increased by 1.76-fold and 2.98-fold, respectively, after treatment, which were similar to that of the normal joints. The effect can be attributed to the partial mediation of SHED exosomes to the NF-κB pathway, and the ability of exosomes to inhibit OA is found not inferior to that of hyaluronic acid.
NEW MATERIAL:The imidazole derivative of formula I (R is H or two Rs together form a bond between C atoms; Y is CN, CH3, C2H5, vinyl, phenyl or benzyl). EXAMPLE:1-Benzyl-(2-phenylethyl)imidazole. USE:A medicine. It exhibits excellent gastric inhibitory action and is expected to be useful as an antiulcer agent. PREPARATION:A compound of formula I wherein two Rs together form a bond between C atoms can be produced e.g. by reacting 1-benzyl-2- formylimidazole of formula II with a compound of formula III in a solvent such as benzene in the presence of n-butyllithium. Another compound of formula I wherein R is H is obtained by the catalytic reduction of the above compound of formula I in a solvent such as methanol in the presence of a catalyst such as Pd/C.
PURPOSE: A ginseng flower powder, a manufacturing method thereof, and cosmetic composition containing thereof are provided to apply for various cosmetics compositions by eliminating spicy smell which is included in the ginseng flowers. CONSTITUTION: A manufacturing method of a ginseng flower comprises the following steps: desiccating ginseng flower and flower stalk; shattering the dried product into pieces; and steaming the crushed material for 10-36 hours. The average particle size of the ginseng flower powder is 10-20 micro meters. The pulverizing device is a blade mill. The cosmetic composition contains the ginseng flower powder. An eliminating method of hot ginseng flower powder comprises the following steps: a step of desiccating the ginseng flower and flower stalk; a step of shattering the desiccant into pieces; and a step of steaming the crushed material for 10-36 hours.
A method of producing the constituents of a therapeutic product from mammalian cells is described herein. Cells are isolated from a mammalian source. The cells are exposed to supercritical carbon dioxide (SCCO 2 ) for 1 to 30 minutes, where the SCCO 2  is maintained at a pressure of 1071 pounds per square inch (PSI) and a temperature of 31.1 to 45 degrees Celsius during the exposure. The exposure dissociates the cellular membranes of the cells to release intramembrane components therein to produce constituents of the therapeutic product. The mammalian cells may include at least one of platelets, stem cells, germ cells, and somatic cells. The methods described herein are particularly advantageous for releasing and capturing therapeutic intramembrane components from platelets and alpha-granules.
Self-weighing is consistently associated with more effective weight control. However, patterns show that participants disengage from their weight control behaviors following weight gain. Women with BMIs in the overweight/obese range (N = 50) enrolled in a long-term behavioral weight loss program completed ecological momentary assessment (EMA) surveys immediately after their daily weigh-ins. Nightly EMA surveys and self-monitoring data through Fitbit measured their weight control behavior that day. On days when participants gained weight (vs. lost or maintained), they reported more negative mood, more guilt/shame, and lower confidence in weight control. Motivation following daily weight gain depended on participants' overall satisfaction with their weight loss so far: more satisfied participants had marginally higher, but less satisfied participants had marginally lower motivation in response to daily weight gain. Greater guilt/shame and lower motivation after the weigh-in predicted less effective weight control behavior that day (e.g., lower likelihood of calorie tracking, fewer minutes of physical activity). Results demonstrate that even small weight gain is distressing and demoralizing for women in BWL programs, which can lead to goal disengagement. These findings have implications for future BWL interventions, including the potential utility of just-in-time adaptive interventions to promote more adaptive responses in the moments after weigh-ins.
The present invention relates to a mouth cavity casting titanium special embedding material and a preparation method and application thereof. The present invention is characterized in that 20 to 70 parts of Al2O3, 15 to 60 parts of MgO, 3 to 15 parts of Mg (H2PO4) 2HO2, 1 to 10 parts of NH4H2PO4, 1 to 10 parts of metal zirconium powder and 1 to 10 parts of AlF3 are added into a ball mill for milling, and is uniformly mixed. The mixture of which the proportion of embedding material powder material to adjusting and stirring liquid is 100 to 20-40 is uniformly adjusted. The mixture is embedded and cast, and a casting ring is disassembled after the embedding material is coagulated and hardened. A casting mould is arranged in a casting titanium special automatic baking oven, and is sintered. The casting mould has the baking procedures that when room temperature rises to 120 to 160 DEG C, the room temperature is kept for 60 to 100 min. When the room temperature rises to 700 to 850 DEG C, the room temperature is kept for 80 to 100 min. When the room temperature continues rising to 1100 to 1250 DEG C, the room temperature is kept for 1 to 3 hours. Then, the room temperature is gradually decreased to 600 to 800 DEG C, and the speed of elevating temperature and the speed of decreasing temperature are both about 5 DEG C/min; after 10 to 12 hours, the casting mould with the constant temperature from 600 to 800 DEG C is put into a casting titanium machine for casting without a ring. A cast casting mould is thrown in cold water for quenching, and a requisite casting is obtained after the embedding material on the casting surface is removed and the casting surface is processed in the sand blasting mode.
Patients randomized to intensive SBP control will be treated to achieve an SBP goal \<120 mm Hg, and patients randomized to standard SBP control will be treated to achieve an SBP goal \<140 mm Hg. Antihypertensive medications will be titrated on the basis of seated blood pressure measurements obtained after a 5-min rest period. All participants will be provided with dietary (e.g., 1500mg/d sodium restriction) and lifestyle recommendations as background therapy for optimizing HTN control.The clinical context may be considered at each visit to inform decision-making regarding treatment initiation or modification, at the discretion of the treating provider.
Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. Coxsackie virus has been detected in human pancreatic beta cells and causes insulitis. This non-destructive islet inflammation does not itself cause diabetes, but this disease will occur if viral infection is followed by a separate autoimmune response. The insulitis is mediated mainly by natural killer cells. Islets from coxsackie virus positive samples displayed reduced insulin secretion in response to glucose and other secretagogues. Virus extracted from positive islets was able to infect beta cells from human islets of non-diabetic donors, causing viral inclusions and signs of pyknosis.
PURPOSE:An antitumor agent, containing D-phenylalanine as an active constituent, and having improved antitumor action, particularly immunological activating action. CONSTITUTION:An antitumor agent containing D-phenylalanine as an active constituent. The D-phenylalanine is a white powder usually slightly soluble in water and known to have the acupuncture and an esthetic action which is considered to be the action through the endorphin. The D-phenylalanine has an inhibitory activity against the activity of carboxyl peptidase A decomposing the endorphin, and the presence of the D-phenylalanine is considered to be the cause for the development of the antitumor and immunological activating action. The endorphin and interferon have the close immunological relation and are similar in structure. Therefore, the D-phenylalanine is believed to exhibit the physiological activity similar to the interferon.
BACKGROUND: Some vaccines have a small risk of triggering Guillain-Barré syndrome (GBS), an autoimmune disorder where nerve damage leads to paralysis. There is a CDC precaution for patients whose GBS was associated with an influenza or tetanus toxoid-containing vaccine (GBS occurring within 42 days following vaccination).
METHODS: We described vaccine patterns before and after a GBS diagnosis with a matched cohort design in a 20% random sample of fee-for-service Medicare enrollees. We defined the index date as an ICD-9-CM or ICD-10-CM GBS diagnosis code in the primary position of an inpatient claim. We matched each GBS patient to five non-GBS comparators on sex, exact age, racial and ethnic category, state of residence and the month of preventive health visits during baseline; used weighting to balance covariates; and measured frequency of vaccines received per 100 people during year before and after the index date using the weighted mean cumulative count (wMCC).
RESULTS: We identified 1567 patients with a GBS diagnosis with at least 1 year of prior continuous enrollment in Medicare A and B that matched to five comparators each. The wMCCs in the 1 year before the index date were similar for both groups, with a wMCC of 74 vaccines/100 people in the GBS group (95% CI 71, 77). Within 1 year after the index date, patients with GBS had received 26 vaccines/100 people (95% CI 23, 28), which was 41 fewer vaccines than matched non-GBS comparators (95% CI -44, -38). Among GBS patients, 11% were diagnosed with GBS within 42 days after a vaccine.
CONCLUSIONS: GBS diagnosis has a strong impact on reducing subsequent vaccination even though there is no warning or precaution about future vaccines for most patients diagnosed with GBS. These data suggest discordance between clinical practice and current vaccine recommendations.
A human carbonyl reductase 1 (CBR1) is a member of an NADPH-dependent short-chain dehydrogenase/reductase superfamily, wherein the family is known to perform an important role for a nerve cell survival with an antacid function. Inventors experimented whether PEP-1-CBR1 fusion protein protects nerve cell from damage due to oxidation stress. The PEP-1-CBR1 fusion protein efficiently permeates an HT-22 cell which is a hippocampus neuron cell and shows protection effects on destruction of neuron due to peroxide. The PEP-1-CBR1 fusion protein permeating the cell remarkably hinders not only destruction of the cell, oxidation of a giant molecule in the cell, and the generation of reactive oxygen but also MARKs activation. Also, the inventors have found that the PEP-1-CBR1 fusion protein remarkably protects the neuron from the destruction of the neuron at a hippocampus CA1 part due to ischemia damage in an animal model. Moreover, the PEP-1-CBR1 fusion protein remarkably reduces the activation of a neuron cell and fat peroxidation in the animal model. These results show that the PEP-1-CBR1 fusion protein remarkably protects the neuron cell from the destruction of the neuron due to the oxidation stress in vitro and in vivo cases. Therefore, the PEP-1-CBR1 fusion protein may be used as a medicine of ischemic damage such as damage and destruction of the neuron.
OBJECTIVES: This study investigated gene polymorphisms in the interleukin-4 (IL-4) and its receptor alpha (IL-4Rα) gene regions in human hosts with uncomplicated malaria.
DATA DESCRIPTION: Blood samples were obtained from a case-control study conducted at the Sogakope district hospital in the Volta region of Ghana. Thick blood films were made and used to detect the presence and levels of parasitaemia in the patient samples. Genotyping of IL-4 (150 C/T) and the IL-4Rα (Pro-478-Ser) polymorphisms in the promoter regions and receptor gene was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) after DNA extraction. The data are useful in determining genetic polymorphisms (allele and genotypic frequencies) of IL-4 and its alpha receptor. In addition, they are useful when comparing levels of parasite density and haematological parameters between genotypic variants of IL-4 and IL-4Rα. These data contribute to our understanding of the genetic basis of malaria susceptibility, particularly in the population of the Volta region of Ghana.
Experiment group A accepted the Integrated-based Laughing Qigong Program (IB-LQP) During the intervention, the participants formed a standing circle and could make eye contact. The time was divided into 10 minutes of warm-up (deep breathing, stretching of muscles, expressing various emotions on the face, stretching of limbs) and 30-40 minutes of main exercise (Breathing and Laughing Qigong practice). The main exercise included using the natural breath of laughter to activate the body, turning a fake smile into a real smile and laughter, using different body movements at the same time, producing a variety of types of laughter, and conducting self-emotional awareness and emotional transformation drills to reduce the backlog.
Idiopathic pulmonary fibrosis (IPF) is a highly debilitating and fatal chronic lung disease that is difficult to cure clinically. IPF is characterized by a gradual decline in lung function, which leads to respiratory failure and severely affects patient quality of life and survival. Oxidative stress and chronic inflammation are believed to be important pathological mechanisms underlying the onset and progression of IPF, and the vicious cycle of NOX4-derived ROS, NLRP3 inflammasome activation, and p38 MAPK in pulmonary fibrogenesis explains the ineffectiveness of single-target or single-drug interventions. In this study, we combined astragaloside IV (AS-IV) and ligustrazine (LIG) based on the fundamental theory of traditional Chinese medicine (TCM) of "tonifying qi and activating blood" and loaded these drugs onto nanoparticles (AS_LIG@PPGC NPs) that were inhalable and could penetrate the mucosal barrier. Our results suggested that inhalation of AS_LIG@PPGC NPs significantly improved bleomycin-induced lung injury and fibrosis by regulating the NOX4-ROS-p38 MAPK and NOX4-NLRP3 pathways to treat and prevent IPF. This study not only demonstrated the superiority, feasibility, and safety of inhalation therapy for IPF intervention but also confirmed that breaking the vicious cycle of ROS and the NLRP3 inflammasome is a promising strategy for the successful treatment of IPF. Moreover, this successful nanoplatform is a good example of the integration of TCM and modern medicine.
The University Hospital in Nancy is an academic regional transgender referral center in Lorraine (France) and keeps a register of subjects available from 2004. The register at the time of the present study (February 2020) included 320 subjects who met diagnostic criteria for gender dysphoria and were seen regularly in the out-patient clinic at our department of endocrinology. Our investigation is a part of the regular care of subjects with gender dysphoria.
OBJECTIVES: Self-compassion is a positive psychological factor linked to improved physical and psychological outcomes across different chronic illness populations. However, the extent to which self-compassion contributes to reduced distress across different conditions or as a function of participant factors is not clear. The current meta-analysis aimed to quantify the association between self-compassion and psychological distress in different chronic illness populations and evaluate the factors that moderate this association.
METHODS: A systematic search of three electronic databases identified research reporting associations between self-compassion and psychological distress in chronic illness. A random effects meta-analysis was conducted to evaluate the association between self-compassion and psychological distress. Moderator analyses were conducted for sample characteristics and distress types. A bespoke tool evaluated study quality.
RESULTS: Searches yielded 51 eligible studies with 57 effect sizes. Meta-analysis revealed that self-compassion was negatively associated with psychological distress (r = -.516; 95% CIs [-.55, -.48]; p = .000). Moderator analyses were significant for distress type and chronic illness group, with effects being largest for stress and neurological conditions. Effects did not vary by sex, age or illness duration.
CONCLUSIONS: Findings from this first comprehensive investigation of the link between self-compassion and distress in chronic illness highlight the protective role of self-compassion for chronic illness populations. These results lay the foundation for further research into understanding the processes that link self-compassion to lower psychological distress, and that examine the effectiveness of self-compassion interventions in chronic illness populations, to further advance knowledge and inform practice in this area.